Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
Hosted on MSN8h
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
JD Supra17h
Mintz IRA Update — A Circuit Win and the End of Chevron Deference Could Shift Tides in Drug Price Negotiation Program Challenges
As detailed in our previous updates, the IRA’s Medicare Drug Price Negotiation Program (the Negotiation Program or Program), ...
Trump's reciprocal tariffs would hit these European Union products that Americans buy the hardest
Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...
STAT22h
Pharmalittle: We’re reading about FDA morale, pharma removing DEI goals, and more
Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...